Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 21;7(12):e018954.
doi: 10.1136/bmjopen-2017-018954.

Investigating fractional exhaled nitric oxide (FeNO) in chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO): a scoping review protocol

Seyed-Mohammad-Yousof Mostafavi-Pour-Manshadi  1   2 , Nafiseh Naderi  1   2 , Miriam Barrecheguren  1   3 , Abolfazl Dehghan  4 , Jean Bourbeau  1   2
Affiliations

Investigating fractional exhaled nitric oxide (FeNO) in chronic obstructive pulmonary disease (COPD) and asthma-COPD overlap (ACO): a scoping review protocol

Seyed-Mohammad-Yousof Mostafavi-Pour-Manshadi et al. BMJ Open. .

Abstract

Introduction: During the last decade, many articles have been published, including reviews on fractional exhaled nitric oxide (FeNO) use and utility in clinical practice and for monitoring and identifying eosinophilic airway inflammation, especially in asthma, and evaluating corticosteroid responsiveness. However, the exact role of FeNO in patients with chronic obstructive pulmonary disease (COPD) and its ability to distinguish patients with COPD and those having concomitant asthma, that is, asthma-COPD overlap (ACO) is still unclear and needs to be defined. Due to the broad topics of FeNO in chronic airway disease, we undertook a scoping review. The present article describes the protocol of a scoping review of peer-reviewed published literature specific to FeNO in COPD/ACO over the last decade.

Methods and analysis: We used Joanna Briggs Institute Reviewers' Manual scoping review methodology as well as Levac et al's and Arksey et al's framework as guides. We searched a variety of databases, including Medline, Embase, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Library, Web of Science, and BioSciences Information Service (BIOSIS) on 29 June 2016. Additional studies will be recognised by exploring the reference list of identified eligible studies. Screening of eligible studies will be independently performed by two reviewers and any disagreement will be solved by the third reviewer. We will analyse the gathered data from article bibliographies and abstracts.

Ethics and dissemination: To investigate the body of published studies regarding the role of FeNO in patients with COPD and its usefulness in the clinical setting, a scoping review can be used as a modern and pioneer model, which does not need ethics approval. By this review, new insights for conducting new research specific to FeNO in COPD/ACO population will emerge. The results of this study will be reported in the scientific meetings and conferences, which aim to provide information to the clinicians, primary care providers and basic science researchers.

Keywords: asthma-copd Overlap (aco); chronic obstructive pulmonary disease (copd); fractional exhaled nitric oxide (feno); scoping review.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Similar articles

See all similar articles

Cited by

References

    1. Aggarwal AN, Gupta D, Agarwal R, et al. . Comparison of the lower confidence limit to the fixed-percentage method for assessing airway obstruction in routine clinical practice. Respir Care 2011;56:1778–84. 10.4187/respcare.01160 - DOI - PubMed
    1. Cataldo D, Corhay JL, Derom E, et al. . A Belgian survey on the diagnosis of asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis 2017;12:601–13. 10.2147/COPD.S124459 - DOI - PMC - PubMed
    1. Barnes PJ. Asthma-COPD overlap. Chest 2016;149:7–8. 10.1016/j.chest.2015.08.017 - DOI - PubMed
    1. Global Initiative for Asthma. Diagnosis of diseases of chronic airflow limitation: asthma, COPD and asthma-COPD overlap syndrome (ACOS). A joint project of GINA and GOLD, 2014.
    1. Lozano R, Naghavi M, Foreman K, et al. . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095–128. 10.1016/S0140-6736(12)61728-0 - DOI - PMC - PubMed

MeSH terms